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Differential transcriptional activation of matrix
metalloproteinase-2 and membrane type-1 matrix
metalloproteinase by experimental deep venous
thrombosis and thrombin
Sia Dahi, BA,a Jackie G. Lee, BA,a David H. Lovett, MD,b and Rajabrata Sarkar, MD, PhD,a
San Francisco, Calif
Objective: Resolution of deep venous thrombosis (DVT) is involved in the pathogenesis of postthrombotic syndrome.
Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that are critical in angiogenesis and tissue
remodeling. We hypothesized that MMP-2 and its membrane-bound activator membrane type-1 matrix metalloprotein-
ase (MT1-MMP) expression would be expressed and activated during the resolution of DVT.
Methods: DVT was generated by caval ligation in wild-type and MMP-2 transgenic reporter mice. Ligated and
sham-operated (control) cavae were analyzed for MMP-2 transcription (–galactosidase activity in MMP-2 reporter
mice) and MT1-MMP mRNA by real-time polymerase chain reaction. MMP-2 activity was determined by zymography,
and immunohistochemical staining for –galactosidase and MT1-MMP protein was used to localize expression. Human
umbilical vascular endothelial cells (HUVEC) were treated with 10 U/mL thrombin and MMP-2 and MT1-MMP
mRNA levels and MMP-2 activity was determined.
Results: MMP-2 activity increased 71% (n  5, P < .05 ) at day 8 in ligated vs control cavae by zymography.
-galactosidase activity showed a 1.2-fold (n  8, P < .05) and 1.7-fold (n  8, P < .05) induction in MMP-2
transcription at day 3 and day 8, respectively. No significant MT1-MMP gene induction was seen at day 3 in ligated vs
control cavae, but MT1-MMP mRNA was upregulated 2.5-fold (n  8, P < .05) in ligated cavae at day 8.
Immunohistochemical staining localized MMP-2 and MT1-MMP expression to the vein wall and cellular infiltrates of the
thrombus. Thrombin-treated HUVEC showed differential responses of MMP-2 and MT1-MMP. Zymography of
conditioned media and cell lysates illustrated a 220% (152.6 8.6 vs 69.445 5.46 pixels/unit area, n 5, P< .05) and
150% (74.1  7.3 vs 49.2  5.7 pixels/unit area, n  5, P < .05) increases in MMP-2 activity respectively. MMP-2
mRNA levels were downregulated 30% (0.48  0.023 vs 0.63  0.035 copies of MMP-2 mRNA/copy GAPDH, n  5,
P < .05), whereas MT1-MMP message was upregulated 250% (0.147  0.009 vs 0.059  0.005 copies of MT1-MMP
mRNA/copy GAPDH, n  5, P < .05).
Conclusions: Resolution of DVT is associated with increased MMP-2 transcription and activity as well as MT1-MMP
expression. Thrombin may mediate the increase in MT1-MMP noted in DVT. This is the first article studying MMP-2
and MT1-MMP transcription in DVT. These findings add DVT resolution to the class of inflammatory and fibrotic
disorders in which transcriptional activation of the MT1-MMP/MMP-2 genes occurs and identify a potential therapeutic
target to modulate this clinically relevant process.
Clinical Relevance: Postthrombotic syndrome remains a significant clinical problem after deep venous thrombosis
(DVT), but the cellular and molecular mechanisms involved in thrombus resolution and vein wall fibrosis remain
undefined. Matrix metalloproteinase (MMP) enzymes are critical to cell migration and matrix breakdown. We identify
gene transcription and activity of two MMP isoforms, MMP-2 and MMP-14 (membrane type MMP 1, MT1-MMP) in
the resolution phase of experimental DVT and in thrombin-treated endothelial cells. These studies define new proteases
potentially important to resolution of DVT and development of postthrombotic syndrome. (J Vasc Surg 2005;42:
539-45.)Deep venous thrombosis (DVT) is a common clinical
problem, with more than 2million new cases per year in the
United States despite heightened public awareness and
increased prophylaxis. Treatment with anticoagulation
therapy prevents propagation of thrombus and pulmonary
embolism. However, anticoagulation does not prevent the
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It is not clear why some patients with DVT will remain
free from postthrombotic syndrome whereas in others with
similar initial patterns of thrombosis chronic symptoms of
venous obstruction develop. These disparate clinical out-
comes suggest that the process of DVT resolution is impor-
tant in determining whether chronic venous obstruction
and reflux will develop. Resolution of DVT occurs clinically
over several weeks2 and often results in recanalization of the
vein. This requires thrombus resolution, which is a complex
process involving clot retraction, fibrinolysis, and angio-
genesis. Studies of experimental venous thrombosis have
shown that thrombus resolution involves infiltration of the
thrombus by inflammatory cells, capillary endothelial cells,
and fibroblasts. The cellular and molecular mediators of
thrombus resolution remain largely undefined, but include
urokinase-type plasminogen activator (uPA)3 and the
CXCR2 cytokine receptor.4
Thematrix metalloproteinase (MMP) family is essential
for cell migration, matrix remodeling, and angiogenesis.
The expression of the principal collagenases (MMP-2 and
MMP-9) is increased in experimental venous thrombosis,4
and these enzymes play a critical role in vascular remodeling
induced by altered arterial flow,5 tissue ischemia,6 and
aortic aneurysms.7 MMP-2 activity is critical for migration
of endothelial cells8 and monocytes/macrophages.9 Tar-
geted deletion of either MMP-210,11 or its cell surface
activator membrane-type 1 MMP (MT1-MMP, MMP-
14)12 abolishes angiogenesis in vivo. Thrombin, a critical
proteolytic mediator in venous thrombosis, cannot cleave
pro-MMP-2 to its active form,13 but increases MMP-2
activity in cultured endothelial cells by increasing expres-
sion of MT1-MMP.14 Pro-MMP-2 can also be proteolyti-
cally activated in vitro by the coagulation proteins activated
protein C (APC)15 and factor Xa.16 Despite these sugges-
tive in vitro reports and the potential importance of
MMP-2 in thrombus resolution, there are no in vivo studies
of MMP-2 and MT1-MMP gene expression and activity in
DVT. The purpose of this study was to characterize the
expression and activation of the MT1-MMP/MMP-2 pro-
teins in experimental DVT and to identify the potential
mechanisms mediating their expression.
MATERIALS AND METHODS
Cell culture. PrimaryHUVEC cultures were obtained
from Cambrex Bio Science (Walkersville, Md) and grown
on 1% gelatin-coated 100-mm dishes.14,17,18 Cells were
cultured in M199 media supplemented with 20% fetal
bovine serum, 50 g/mL endothelial cell growth factor
(Biomedical Technologies, Stroughton, Mass), and 10
U/mL heparin, in 5% CO2 at 37°C. All experiments were
performed on cells between passages 3 to 6. Cells were
washed twice with serum-free M199 media and incubated
for 24 hours in serum-free media supplemented with 1%
(w/v) Bovine Serum Albumin (BSA) with or without 10
U/mL bovine plasma thrombin (T7513, Sigma, St. Louis,
Mo) stimulation. The conditioned media was collected andcentrifuged 5000g for 10 minutes to remove cellular de-
bris. Cells were lysed in M-Per mammalian protein cell lysis
buffer per manufacture instructions (Pierce, Rockford, Ill).
Supernatants were stored at70°C for use in zymography.
Transgenic mouse construction. The starting mate-
rials were plasmid p41 containing a 5-kb genomic fragment
of the rat MMP-2 gene extending from1686 (relative to
the transcriptional start site) to the middle of the second
exon, and p1.2 containing a polylinker 5= to an SV40
polyadenylation signal and paired NotI sites flanking the
entire insert. TheMMP-2 coding sequence start codon was
first mutated to TAG using mutagenic oligonucleotides.
The entire 5-kb fragment was amplified by polymerase
chain reaction (PCR) adding 5= MluI and a 3= KpnI sites
and cloned into p1.2 upstream from the SV40 polyadenyl-
ation site. An Escherichia coli -galactosidase gene was
isolated by PCR adding a 5= KpnI site (and Kozak se-
quence) and a 3= XhoI site. This was ligated between the
MMP-2 promoter and the SV40 polyadenylation sequence
to produce F8- gal. The transcriptional unit was freed
from the plasmid backbone using the paired flanking NotI
sites. Purified endotoxin-free plasmid DNA was injected
into outbred CD-1 mouse embryos. Stable founder lines
were created and bred to homozygosity using standard
mouse breeding and backcrossing techniques. Tail DNA
from each animal was analyzed before experimental use to
confirm transgenic genotype.
Surgery. Transgenic and outbred CD-1mice (Charles
River Laboratories, Wilmington, Mass) weighing between
20 and 30 g under ketamine (80 mg/kg I.P) and xylazine
(16 mg/kg intra-peritoneal) anesthesia underwent a lapa-
rotomy in which the infrarenal inferior vena cava (IVC) was
ligated with 6-0 nonabsorbable suture and lumbar
branches of the IVC were divided. Control animals under-
went a sham ligation in which the IVC was dissected free
and branches were divided, but proximal ligation of the
IVC was not performed. Mice were euthanized at 3 and 8
days postoperatively. Control vena cavae and ligated vena
cavae (with thrombus that is inseparable) were excised and
processed for either RNA, protein, or immunohistochem-
istry. In more than 90% of ligated mice a reproducible large
(1 cm) thrombus developed, and cavae that did not show
large thrombi were not included in the study. All proce-
dures were performed according to protocols approved by
the Institutional Animal Care and Use Committee.
Quantitative real-time PCR. Surgically excised IVC
(n  8 each) were immediately homogenized in 1 mL of
Tri-Reagent (Molecular Research Center, Cincinnati, Oh)
per manufacturer instructions, and 1 to 3 g of total RNA
was used to generate cDNA with a Super Script III First
Strand Synthesis Kit (Invitrogen, Carlsbad, Calif). Using
SYBR Green Master Mix and an ABI Prism 7900HT
detection system (Applied Biosystems, Foster City, Calif),
cDNA was amplified, for 40 cycles, 15 seconds at 95°C and
60 seconds at 60°C. MT1-MMP mRNA levels were nor-
malized to GAPDH mRNA in each sample. Samples were
run in triplicate to ensure amplification integrity. The prim-
ers used were as follows: MT1-MMP: (forward) 5=-TGGT-
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GACCCTGACTTGTTCCATA-3= GAPDH : (forward)
5=-TGCACCACCAACTGCTTAG- 3= and (reverse) 5=-
GGATGCAGGGATGATGTTC-3=.
Zymography and -galactosidase assay. Control-
operated (n  8) and ligated IVC (n  8) were homoge-
nized in the M-Per mammalian protein cell lysis buffer
(Pierce) or Promega -galactosidase reporter lysis buffer
(Promega, Madison, Wis). Samples were then centrifuged
(14,000 rpm, 15 min) and supernatants were frozen at
70°C. Total protein in all samples was determined by
BCA assay (Pierce). Zymography was performed on IVC
and HUVEC media as previously described19,20 using 25
g of protein loaded on a 10% SDS-polyacrylamide/1%
gelatin gel (Invitrogen) run at 125 V for 90 minutes.
Molecular weights of protein bands were confirmed by
using Mark 12 unstained zymographic molecular weight
marker (Invitrogen). Densitometry was done with NIH
Image J software (public domain). For -galactosidase
assay, 20 g lysate was incubated at room temperature with
200 L chemiluminescent substrate for 1 hour (BD Bio-
sciences, Palo Alto, Calif). -galactosidase activity was de-
termined with a luminometer (TD 20/20, Turner Designs,
Sunnyvale, Calif).
Immunohistochemistry. Control (n  5) and ligated
IVCs (n  5) were excised, fixed in 4% buffered paraformal-
dehyde, paraffin embedded, and serially cross-sectioned 5m
thick. Slides were deparaffinized in xylene, followed by rehy-
dration in graded ethanol washes. Endogenous peroxidase
activity was blocked by washing sections in 3% H2O2 for 5
minutes. Sections were incubated with avidin-biotin blocking
solution (Vector Laboratories, Burlingame, Calif) and stained
with a mouse-on-mouse kit (Vector Laboratories). Sections
were incubated with either a monoclonal anti--galactosidase
(catalog No. CRM7001M, Cortex Biochem, San Leandro,
Calif) or a monoclonal MT1-MMP (catalog No. RDI-
MT1MMPabm-B7, Research Diagnostics, Flanders, NJ) an-
tibody at a 1:250 dilution overnight at 4°C, followedwith the
anti-mouse immunoglobulin (Ig) G biotinylated secondary
antibody at a 1:250 dilution for 30 minutes. Sections were
incubated with Vectastatin Elite ABC reagent for 5 minutes
and developed with Vector VIP Substrate Kit for Peroxidase
(Vector Laboratories). Slides were subsequently mounted
with VectaMount (Vector Laboratories). Staining controls
included staining with no primary antibody and mouse IgG
(Santa Cruz Biotechnology, Santa Cruz, Calif). Staining in-
tensity was quantitated by pixel analysis (NIH Image).
Statistical analysis. All data are presented as mean 
standard error. All experiments were repeated at least three
times with similar findings to confirm reproducibility.
Power calculations were done to ensure adequate sample
sizes. Unpaired Student’s t-test was used to compare con-
trol and ligated samples. P  .05 was defined as statistical
significance.
RESULTS
Deep venous thrombus induces MMP-2 activity.
Caval ligation reproducibly produced a thrombus at 3 and8 days after infrarenal ligation of the IVC (Fig 1A). Hema-
toxylin and eosin staining of both control and ligated IVC
at day 8 showed cellular infiltrates within the thrombus as
well as vein wall inflammation (Fig 1B). We studied
MMP-2 and MT1-MMP in thrombus at day 8 because
prior studies have shown that thrombus resolution occurs
at this time point.4
In ligated IVC, we noted induction of MMP-2 activity
(Fig 2A) by zymography at day 8. Densitometry of zymo-
gram gels confirmed a 70% increase in active MMP-2 in
ligated vs control cavae (140.2  14.3 vs 83.5  7.85
pixels/unit area, n  5, P  .05). Similarly there was an
increased ratio of active MMP-2 to pro-MMP-2 in the
ligated cavae vs the control (1.31 0.089 vs 1.01 0.046,
n  5, P  .05). At day 3, when thrombus size is increas-
ing,4,21 MMP-2 activity (Fig 2A) was not statistically dif-
ferent between ligated and control IVC (82.8  2.73 vs
79.5 3.84 pixels/unit area, n 5, NS). As expected, the
ratio of active MMP-2 to pro-MMP-2 was statistically the
same (0.623 0.019 vs 0.601 0.023, n 5, PNS) at
day 3.
We studied MMP-2 activity in the superior vena cava
after IVC ligation to ensure thatMMP-2 activity in the IVC
was not a result of a systematic inflammatory response.
Fig 1. Mouse model of deep venous thrombosis. A, Ligation of
the infrarenal inferior vena cava (IVC) causes thrombus to develop.
Arrowhead represents the location of the infrarenal ligature of the
IVC. B, Representative sectioning of control and deep venous
thrombosis (DVT) with hematoxylin and eosin counterstaining 8
days after IVC ligation (400 magnification). The vein wall is
labeled by a single arrowhead.There was approximately a 3.0-fold difference (28.5 5.26
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levels of MMP-2 between ligated IVC and the superior
vena cava (SVC) (Fig 2D). In addition, there was an
increased ratio of active MMP-2 to pro-MMP-2 in the IVC
as compared with the SVC (0.703  0.013 vs 0.336 
0.0765, n  5, P  .05).
DVT induces MMP-2 transcription in the F8 re-
porter mouse. We examined DVT-induced MMP-2 tran-
scription by using the F8 transgenic mouse, which contains
1686 to 3400 bp of the rat MMP-2 gene (including the
first two exons), coupled to a -galactosidase reporter
cassette (Fig 2B). -galactosidase assays of the ligated IVC
relative to control showed a 1.2-fold (n  8, P  .05) and
1.7-fold (n  8, P  .05) induction in MMP-2 transcrip-
Fig 2. Deep venous thrombosis (DVT) and matrix metallopro-
teinase (MMP)-2 activity and gene transcription in F8 transgenic
mouse. A, Representative gelatin zymography 3 and 8 days after
inferior vena cava (IVC) ligation. MMP-2 activity showed no
significant difference at 3 days, but a noticeable induction in
MMP-2 activity is observed at day 8.B,A schematic diagram of the
F8MMP-2 reporter mouse: 5086 bp of ratMMP-2 genomicDNA
(including first two exons) with -galactosidase reporter cassette.
Arrow indicates MMP-2 transcription start site. Asterisk indicates
mutated translational start site. C, –galactosidase assay of control
and DVT 3 and 8 days after ligation shows increased activity
representing transcriptional activation of the MMP-2 gene; n 8,
*P  .05. D, Representative gelatin zymography of the IVC and
superior vena cava of a mouse in which DVT was induced to
illustrate that elevated levels of MMP-2 in DVT are not a result of
a systematic inflammatory response.tion at days 3 and 8 respectively (Fig 2C). Immunohisto-chemical staining for the -galactosidase protein was done
to identify cells in which MMP-2 transcription occurred.
Expression was seen in both the vein wall and thrombus
(Fig 3A), and quantitation of immunostaining showed
similar intensity of -galactosidase immunoreactivity be-
tween vein wall and thrombus (10,207 349 vs 10,090
151, n  5, P  NS). -galactosidase staining outside the
vein wall suggests the possible importance of MMP-2 in
perivenous inflammation. Staining withmouse IgG in place
of a primary antibody showed minimal staining in all spec-
imens (Fig 3B).
MT1-MMP gene expression and protein are in-
creased in DVT. We examined MT1-MMP mRNA and
protein in DVT by real-time PCR and immunohistochem-
istry, respectively. Although no significant induction of
MT1-MMP mRNA was seen at day 3 (Fig 4A, 0.07 
0.014 vs 0.06 0.005 copies of MT1-MMPmRNA/copy
of GAPDH, n  8, NS), MT1-MMP mRNA was upregu-
lated more than twofold (0.39  0.068 vs 0.14  0.043
Fig 3. Localization of deep venous thrombosis (DVT)-induced
matrix metalloproteinase (MMP)-2 expression. A, Immunohisto-
chemical staining for -galactosidase (brown color) in control and
DVT vein. Staining (single arrowheads) is evident in both the vein
wall and thrombus of the DVT (400 magnification). B, Mouse
immunoglobulin G was used in place of the primary antibody as
control (400 magnification). The vein wall is labeled by double
arrowheads, and staining is indicated by a single arrowhead.copies ofMT1-MMPmRNA/copy of GAPDH, n 8, P
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Immunohistochemical staining for MT1-MMP at day 8
showed a distribution similar to the expression pattern
noted in the F8 transgenic mouse. Staining was present in
both the vein wall and cellular components of the thrombus
(Fig 4C).
Thrombin induces MMP-2 activity and MT1-
MMP mRNA in HUVEC. We treated HUVEC with
activated thrombin andmeasuredMMP-2 activity,MMP-2
mRNA, and MT1-MMP mRNA. Zymography of condi-
tioned media from HUVEC cells 24 hours after thrombin
treatment illustrated a 2.2-fold increase in secreted active
MMP-2 (Fig 5C) relative to untreated cells (152.6  8.6 vs
69.445 5.46 pixels/unit area, n 5, P .05). The ratio
of active to pro-MMP-2 was two-fold greater in the treated
cells vs control (0.855 0.046 vs 0.396 0.056, n 5, P
 .05). Zymography of cellular lysates (Fig 5C), paralleling
conditioned media, showed a 1.5-fold increase in active
MMP-2 (74.1 7.3 vs 49.2 5.7 pixels/unit area, n 5,
P  .05). However, the ratio of active to pro-MMP-2 in
thrombin treated cells vs control was not significant (0.461
 0.052 vs 0.424  0.052, n  5, n  NS). Although
Fig 4. Membrane-bound activator membrane type-1matrix met-
alloproteinase (MT1-MMP) gene and protein expression is ele-
vated in deep venous thrombosis (DVT). A, Real-time polymerase
chain reaction analysis of MT1-MMP mRNA levels in control and
ligated inferior vena cavae at 3 and 8 days after ligation. n 8 each,
*P  .05. B, Histologic staining with a MT1-MMP antibody
shows increased expression relative to control of MT1-MMP in
both the vein wall and thrombus (400 magnification). The vein
wall is labeled by double arrowheads, and staining is indicated by a
single arrowhead.MMP-2 activity increased, MMP-2 mRNA levels weredownregulated 30% by real-time PCR in thrombin-treated
cells (Fig 5A, 0.48  0.023 vs 0.63  0.035 copies of
MMP-2 mRNA/copy of GAPDH, n  5, P  .05). This
thrombin treatment caused a 2.5-fold upregulation in
MT1-MMP gene levels after 24 hours (Fig 5B, 0.147 
0.009 vs 0.059  0.005 copies of MT1-MMP mRNA/
copy of GAPDH, n  5, P  .05).
DISCUSSION
We studied the expression of MMP-2 and MT1-MMP
(MMP-14) in experimental DVT and cultured endothelial
cells. The significant findings in this study are: first, venous
thrombosis induces MMP-2 transcription and activity; sec-
ond, MT1-MMP transcription and protein expression are
increased by venous thrombosis; third, thrombin treatment
of endothelial cells induces MMP-2 activity, but not
MMP-2 gene transcription; and fourth, thrombin treat-
ment of endothelial cells induces MT1-MMP gene tran-
Fig 5. Thrombin induces differential transcriptional expression
and activity of matrix metalloproteinases (MMP)-2 and mem-
brane-bound activator membrane type-1 matrix metalloproteinase
(MT1-MMP) in cultured endothelial cells. A, MMP-2 mRNA
levels determined by real-time polymerase chain reaction after a
24-hour 10-U/mL thrombin treatment in human umbilical vas-
cular endothelial cells (HUVEC), n 5, *P .05. B, MT1-MMP
mRNA levels in thrombin-treated and control HUVEC, n 5, *P
 .05. C, Gelatin zymography of conditioned media and cell
lysates of thrombin-treated and control HUVEC.scription.
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reporter mouse to identify areas within the resolving
thrombus and the vein wall where MMP-2 transcription
occurs.
We studied MMP gene activation at day 3 and day 8
because thrombus size is increasing on day 3 and thrombus
resolution is ongoing at day 8. Time points beyond day 8
are not associated with significant further decreases in
thrombus size,4 and the lack of activation of MMP-2 and
MMP-14 at day 3 specifically links these enzymes to the
period of thrombus resolution. Comparison with the dis-
tribution ofMT1-MMP expression within the vein wall and
thrombus reveals co-localization of MMP-2 and MT1-
MMP immunoreactivity, a finding that is consistent with
the requirement for activation of pro-MMP-2 by cell sur-
face MT1-MMP. Comparison of the pro and active
MMP-2 isoforms indicates that DVT in vivo and thrombin
treatment of HUVEC increased pro-MMP-2 levels and
concurrently the ratio of active to pro-MMP-2. The finding
of MMP-2 transcription and MT1-MMP protein within
the thrombus shows that these proteases are being pro-
duced by cells infiltrating the thrombus, rather than by
deposition of circulating MMP-2. These cells within the
thrombus may be both inflammatory cells and capillary
endothelial cells, supporting the study of MMP gene acti-
vation in cultured endothelial cells. Both MMP-14 and
MMP-2 may have diverse functions in thrombus resolu-
tion, because MMP-14 can cleave fibrinogen and thus
contribute to plasmin-independent fibrinolysis.22
Our finding that thrombin inducesMT1-MMP expres-
sion in endothelial cells provides a potential mechanism to
explain the induction of MT1-MMP identified in vivo
within the thrombus. We used HUVEC because these cells
have been extensively studied with regard to thrombin-
induced MMP-14 expression and MMP-2 activation.13,14
This finding is in agreement with previous studies that have
suggested that the activation of MMP-2 protein by throm-
bin is not caused by increased transcriptional activation of
MMP-2, but rather by increased pro-MMP-2 processing by
MT1-MMP.14 The effect of thrombin on MMP-14 expres-
sion requires proteolytic activity, and thus anticoagulation
may inhibit thrombin-induced MMP14 expression and
MMP-2 activation.14 The decrease in MMP-2 mRNA in
response to thrombin (Fig 5A) may reflect feedback inhi-
bition of MMP-2 transcription by the net increase in active
MMP-2 induced by thrombin.
Our finding that MMP-2 transcription is induced by
DVT in vivo but not by thrombin in vitro suggests that
there are thrombin-independent factors that drive MMP-2
transcription in the resolving thrombus and vein wall. The
cellular and molecular mechanisms that drive MMP-2 tran-
scription after thrombosis will thus require study in vivo,
and transgenic reporter mice carrying specific deletions in
the MMP-2 promoter are under development in our labo-
ratory to aid in these investigations.
This is the first study of expression of the MMP-2/
MT1-MMP genes in thrombosis in vivo, and our finding
that MMP-2 gene transcription is induced by thrombusformation is significant given the lack of induction of
MMP-2 gene expression by thrombin and other stimuli in
prior in vitro studies.14 Cell culture studies of MMP-2
transcription are hampered by the fact that cultured cells
continuously produce pro-MMP-2 and do not increase
transcription with cytokine treatment, phorbol esters, or
other stimuli, leading investigators to consider MMP-2
expression as constitutive.17 By contrast, in vivo studies of
limb ischemia,23 neointimal hyperplasia,24 and aneurysm
formation7 show induction of MMP-2 transcription by a
variety of inflammatory and tissue-remodeling stimuli. The
importance of MMP-2 as a mediator of disease is supported
by the elevated circulating MMP-2 levels in patients with
cerebral aneurysms,25 liver fibrosis,26 advanced breast can-
cer,27 and hypertrophic cardiomyopathy.28 Our finding of
thrombus-induced MMP-2 transcription adds thrombus
resolution to the class of disorders in which transcriptional
activation of the MT1-MMP/MMP-2 genes occurs. As
further studies delineate whether MMP-2 activity acceler-
ates or impairs thrombus resolution, augmentation or inhi-
bition of these genes may be a potential therapeutic target
to modulate this clinically relevant process.
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